To facilitate a better understanding of the molecular heterogeneity of breast cancer and to uncover gene-survival associations that segregate with distinct molecular subtypes, we recently compiled a meta-analytical database of over 2,000 human breast tumor expression profiles variously annotated for clinical and pathological variables and derived from various institutions worldwide. This database was utilized for the breast tumor study cited below: Nagalla, et. al., Genome Biology, 2013. While the majority of the tumor expression profiles included in this database derived from publicly accessible microarray repositories, a number of the samples had not been previously published. Here, we describe the origin of these samples and provide their associated clinical and pathological annotations with the hope that other investigators will be able to utilize these data in their own research.
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.
Age, Disease stage
View SamplesSeventy-one breast cancer patients with stages II and III breast cancer were included. They received four preoperative cycles of a weekly PCb (paclitaxel plus carboplatin) regimen. The purpose of this study was to examine the predictive value of the ER pathway for a response to chemotherapy using a gene microarray method. In addition, this study aimed to identify novel ER-related genes, which, combined with ER levels, would provide a robust multi-variable prediction of patient outcome to chemotherapy.
No associated publication
Sex, Age, Specimen part
View SamplesWe evaluated mammary gland responses over time in pubertal female cynomolgus macaques fed diets containing either casein/lactalbumin or soy protein that contained a human-equivalent dose of 120 mg isoflavones/day for ~4.5 years spanning menarche. We assessed estrogen receptors (ERs) expression, and markers of ER activity and estrogen metabolism. Promoter methylation of ERs and their downstream targets was also evaluated. As we found that pubertal soy exposure resulted in transient effects on mammary ER-a transcription after menarche with subtle effects on differentiation and ER activity, a gene expression microarray was performed on a subset of samples as an exploratory approach to investigate potential pathways and gene sets that may be of importance during this post-menarchal breast development.
No associated publication
Sex, Specimen part
View SamplesAs a transcription factor, SOX7 suppresses cancer development. However, only a few genes were demonstrated as SOX7-activated targets in cancer-irrelevant contexts. We used microarray chips to determine SOX7 target genes in breast cancer cells and discovered multiple signaling pathways altered by ectopic SOX7. We also investigated several genes for their roles in SOX7-mediated tumor suppression. Our study innovatively revealed SOX7 target gene profile in a cancer-relevant context and identified several SOX7-repressed target genes.
SOX7 Target Genes and Their Contribution to Its Tumor Suppressive Function.
Sex, Specimen part, Cell line
View SamplesTo test the effect of silencing Rae1 on expression on RNA polymerase II transcripts, host mRNAs were analysed by cDNA microarrays. We hypothesized that if silencing Rae1 expression increases cellular resistance to inhibition of transcription in VSV infected cells, mRNA characteristic of host antiviral response would be increased than compared to cells transfected with control siRNA.
Complexes of vesicular stomatitis virus matrix protein with host Rae1 and Nup98 involved in inhibition of host transcription.
Cell line
View SamplesTo determine if there are differences in the gene expression profile of peripheral blood mononuclear cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who responded to CPI-613 when compared to those patients who did not respond we generated gene expression profiles from four responding patients and compared them to four non-responders. None of the gene expression profiles have been previously published. Here we describe the origins and provide associated clinical annotations with the hope that other investigators will be able to utilize this data in their own research.
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Sex, Age, Specimen part, Disease
View Samples